1019 related articles for article (PubMed ID: 22994348)
41. Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
Kasperska-Zajac A; Brzoza Z; Rogala B
Vaccine; 2007 May; 25(18):3595-8. PubMed ID: 17291641
[TBL] [Abstract][Full Text] [Related]
42. [Clinical efficacy of subcutaneous and sublingual immunotherapy in mite-sensitized patients with allergic rhinitis].
Zhu L; Zhu LP; Chen RX; Tao QL; Lu JH; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Dec; 46(12):986-91. PubMed ID: 22336009
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
[TBL] [Abstract][Full Text] [Related]
44. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity asthmatic children sensitized to house dust mites following sublingual immunotherapy.
Silvestri M; Spallarossa D; Battistini E; Sabatini F; Pecora S; Parmiani S; Rossi GA
J Investig Allergol Clin Immunol; 2002; 12(1):52-9. PubMed ID: 12109533
[TBL] [Abstract][Full Text] [Related]
45. Clinical effects of specific immunotherapy: a two-year double-blind, placebo-controlled study with a one year follow-up.
Dokic D; Schnitker J; Narkus A; Cromwell O; Frank E
Prilozi; 2005 Dec; 26(2):113-29. PubMed ID: 16400234
[TBL] [Abstract][Full Text] [Related]
46. Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?
Rondon C; Sánchez-Borges M; Cupello ER; Fabiano F; Capriles-Hulett A
Allergol Immunopathol (Madr); 2021; 49(2):31-39. PubMed ID: 33641291
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice.
Ferrés J; Justicia JL; García MP; Muñoz-Tudurí M; Alvà V
Allergol Immunopathol (Madr); 2011; 39(3):122-7. PubMed ID: 20570032
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in patients with allergic rhinitis].
Li TY; Chen DH; Lin ZB; Xu R
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Oct; 46(10):859-62. PubMed ID: 22321427
[TBL] [Abstract][Full Text] [Related]
49. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
[TBL] [Abstract][Full Text] [Related]
50. Association between biomarkers and house dust mite sublingual immunotherapy in allergic asthma.
Hoshino M; Akitsu K; Kubota K; Ohtawa J
Clin Exp Allergy; 2020 Sep; 50(9):1035-1043. PubMed ID: 32557974
[TBL] [Abstract][Full Text] [Related]
51. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
[TBL] [Abstract][Full Text] [Related]
52. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites.
Bahceciler NN; Arikan C; Taylor A; Akdis M; Blaser K; Barlan IB; Akdis CA
Int Arch Allergy Immunol; 2005 Mar; 136(3):287-94. PubMed ID: 15722639
[TBL] [Abstract][Full Text] [Related]
53. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
[TBL] [Abstract][Full Text] [Related]
54. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study.
Mortemousque B; Bertel F; De Casamayor J; Verin P; Colin J
Clin Exp Allergy; 2003 Apr; 33(4):464-9. PubMed ID: 12680861
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Der p1-specific antibody levels in children with allergic airway disease and healthy controls.
Aydogan M; Mete N; Yazi D; Akkoc T; Ozdemir C; Blaser K; Akdis M; Akdis C; Bahceciler N; Barlan I
Pediatr Allergy Immunol; 2007 Jun; 18(4):320-5. PubMed ID: 17584311
[TBL] [Abstract][Full Text] [Related]
56. Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil.
Guimarães Junqueir de Queirós M; Oliveira Silva DA; Alves R; Fukuhara Chiba H; Soares de Amaral VB; de Almeida KC; Ynoue LH; de Oliveira Resende R; Camargo Sopelete MC; Rodrigues Silva Segundo G; Ferreira de Sousa Moreira P; Sung SJ; Taketomi EA
J Investig Allergol Clin Immunol; 2008; 18(2):84-92. PubMed ID: 18447136
[TBL] [Abstract][Full Text] [Related]
57. Sublingual immunotherapy to house dust mite in pediatric patients with allergic rhinitis and asthma: a retrospective analysis of clinical course over a 3-year follow-up period.
Nuhoglu Y; Ozumut SS; Ozdemir C; Ozdemir M; Nuhoglu C; Erguven M
J Investig Allergol Clin Immunol; 2007; 17(6):375-8. PubMed ID: 18088019
[TBL] [Abstract][Full Text] [Related]
58. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
[TBL] [Abstract][Full Text] [Related]
59. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients.
Bozek A; Starczewska-Dymek L; Jarzab J
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):77-82. PubMed ID: 28668244
[TBL] [Abstract][Full Text] [Related]
60. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
